<DOC>
	<DOC>NCT00523315</DOC>
	<brief_summary>To describe patients' compliance of taking Aromatase Inhibitor as an adjuvant treatment in the postmenopausal, early breast cancer as seen under current practice</brief_summary>
	<brief_title>APOLLO(Aromatase Inhibitor Patient cOmpLiance Program With qoL Questionaire)</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Aromatase Inhibitors</mesh_term>
	<criteria>Provision of written informed consent Patients with early breast cancer who are scheduled to receive firstline adjuvant endocrine therapy with aromatase inhibitor under the routine clinical practice Histologically or cytologically proven to be HR+(ER or PR +) Postmenopausal woman, defined as a woman fulfilling any of the following criteria(by the local guideline): Age &gt;= 50 years Age &lt; 50 years with amenorrhoea &gt; 12 months and an intact uterus FSH levels within postmenopausal range (over 3040 IU/ml), or Having undergone a bilateral oophorectomy. No other concomitant endocrine therapy such as estrogen therapy or selective estrogen receptor modulators Recurrence of breast cancer Known hypersensitivity to aromatase inhibitor or to any of the excipients Any severe concomitant condition which makes it undesirable for the patient to participate in the trial or which would jeopardize compliance with the trial protocol Previous inclusion in the present study Participation in a clinical study during the last 30 days</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>Aromatase Inhibitor</keyword>
	<keyword>Breast Cancer</keyword>
	<keyword>compliance</keyword>
	<keyword>Naturalistic</keyword>
	<keyword>Observational</keyword>
</DOC>